Background: Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease evolving through multistep carcinogenesis, one of the steps being genetic alterations. Noninvasive identification of HNSCC-specific genetic alterations using saliva would have immense potential in early diagnosis and screening, particularly among high-risk patients.
Design: In this exploratory study, a prospective cohort of 27 HNSCC and 10 healthy controls was examined to determine whether genetic alterations (losses and gains) in saliva DNA differentiated HNSCC patients from normal controls. Saliva DNA was interrogated by a candidate gene panel comprising 82 genes using the multiplex ligation-dependent probe amplification assay.
Results: Eleven genes showed some predictive ability in identifying HNSCC cases from normal controls: PMAIP1, PTPN1, ERBB2, ABCC4, UTY, DNMT1, CDKN2B, CDKN2D, NFKB1, TP53, and DCC. Statistical analysis using the Classification and Regression Tree (CART) identified 2 genes, PMAIP1 and PTPN1, which correctly discriminated all 27 HNSCC patients (100%) from normal controls. Results were validated using the leave-one-out validation approach.
Conclusions: Noninvasive high-throughput multiplex ligationdependent probe amplification identified discrete gene signatures that differentiated HNSCC patients from normal controls providing proof-of-concept for noninvasive HNSCC detection.
Key Words: noninvasive, head and neck squamous cell carcinoma, genetic alterations, multiplex ligation-dependent probe amplification assay (MLPA), classification and regression tree (CART) (Diagn Mol Pathol 2009;18:81-87) H ead and neck squamous cell carcinoma (HNSCC) is a significant health concern worldwide with a prevalence of more than 1.6 million cases. 1 In the United States, its estimated incidence for 2006 was 30,990, and caused over 7400 deaths. 2 Despite rapid advances in the treatment of HNSCC, 5-year survival has only marginally improved from 54.4% to 59.4% over the past 2 decades. 1, 3 Survivors suffer serious and devastating morbidities including speech and swallowing problems, disfigurement, and exorbitant healthcare costs. 4 The poor outcome for HNSCC has been explained predominantly on the basis of late detection of cases. 5 Early detection through screening seems an obvious solution. 6 Currently used screening by clinical examination is complex and presents with several challenges even in a primary care setting. [7] [8] [9] Hence, there is a need to develop screening tests that are effective in routine clinical practice. Molecular approaches seem promising in this regard.
Molecular alterations occur early in HNSCC. 10 Acquisition of a fully malignant phenotype is a stepwise progression defined by several genetic alterations at 3p, 4q, 5q, 6p, 9p, 11q, 13q, 17p, 18q, and 20q. [11] [12] [13] [14] Genetic alterations confer upon the malignant cells characteristics that determine tumor behavior. 14 However, no single molecular event is sufficient to accurately predict the pathobiology of HNSCC. Recently developed highthroughput assays permit detection of alterations in a large number of gene targets. Identification of HNSCCspecific genetic alterations can potentially serve as clonal molecular signatures to differentiate tumor cells from their normal counterparts.
Once established, these molecular HNSCC signatures may have clinical utility as diagnostic, prognostic, and therapeutic biomarkers. This approach can produce validated marker panels for screening purposes, comprising of candidate gene probes specific for HNSCC. 15 As genetic alterations occur before phenotypic expression of cancer, 5 they have the potential to serve as biomarkers for early detection. 10 Head and neck cancers bathe in readily accessible saliva secretions. Saliva being a noninvasive patient sample has immense potential for use in screening programs. As there is no patient discomfort, repeat samples can be collected, which are important for screening and tumor surveillance. In HNSCC patients, saliva contains exfoliated cancer cells harboring genetic alterations. 15 Thus, it offers a potential noninvasive source to examine genetic alterations in HNSCC patients.
The multiplex ligation-dependent probe amplification (MLPA) assay is a recent high-throughput genetic technique allowing simultaneous interrogation of 41 genes using scant amounts (20 ng) of DNA. 14, 16 Validated by using real-time polymerase chain reaction (PCR), it has been used in a wide variety of samples including cell lines, tissue specimens, and even saliva. 14, [16] [17] [18] [19] [20] [21] It can be used for the detection of genetic alterations (losses and gains) 14, 16, 21 and to evaluate epigenetic alterations. 17, 18 It is distinctly advantageous over currently available genetic technologies such as comparative genomic hybridization or DNA chip hybridization methods. 14, 19, 20 Requiring minimal sample preparation, it is an easy-to-perform, cost-effective, time-saving, and reproducible 1-tube assay (in comparison with array-based technology). As each component of the test is fluid, quality control is simpler in comparison with DNA microarrays.
In this exploratory analysis, we analyzed a noninvasive saliva approach to detect HNSCC-specific genetic alterations using MLPA.
MATERIALS AND METHODS

Study Subjects
Thirty-seven subjects, 27 HNSCC patients and 10 normal controls, were studied. Of the 27 HNSCC patients, 11 were early-stage (I/II) and 16 were late-stage (III/IV) tumors located in the upper aerodigestive tract, including 7 in the oral cavity, 2 in the oropharynx, 8 in the larynx, 5 on the tonsil, and 1 in the pyriform sinus; 4 cases had unknown primary squamous cell carcinoma metastatic to the neck. Only untreated patients were included in the study. Normal controls were healthy volunteers with no benign/malignant lesions. All study patients were over 18 years of age. Informed consent was obtained according to the institutional review board-approved protocols.
Sample Collection
Two milliliters of saliva was collected from each study subject in Oragene kits (DNA Genotek Inc, Ontario), and saliva DNA was extracted according to the manufacturer's instructions.
Genetic Analysis
Saliva DNA was interrogated for gene copy number alterations (losses and gains) using the MLPA assay. Two gene probe panels, p005 and p006 (www.mlpa.com), comprising 82 genes, were examined. The panels detect primarily oncogenes and tumor suppressor genes that are located at chromosomal segments that have been implicated in cancer and are distributed throughout the genome. 21, 22 MLPA analysis was performed as outlined previously. 14, 16 Briefly, probes added to the samples were amplified and quantified instead of target nucleic acids.
Amplification of probes by PCR depends on the presence of probe target sequences in the sample. Each probe consists of 2 oligonucleotides, 1 synthetic and 1 M13derived, each hybridizing to adjacent sites of the target sequence. Such hybridized probe oligonucleotides, when ligated, permit subsequent amplification. Ligated probes have identical end sequences, permitting simultaneous PCR amplification using only 1 primer pair. Each probe gives rise to an amplification product of unique size between 130 and 480 bp. Probe target sequences are small (50 to 70 nucleotides). The prerequisite of a ligation reaction provides the opportunity to discriminate single nucleotide differences. The amplified fragments are separated on a DNA sequencer ( Fig. 1 ). Quantification of loss or gain of gene loci is determined through a process of normalization. 14, 16 The peak area for each probe is expressed as a percentage of the total surface area of all peaks of a sample in an assay run ( Fig. 1 ). The relative copy number for each probe is obtained as a ratio of the normalized value for each locus (peak) of the sample to that of the normal control, and in general, the copy numbers in a range of 0.75 to 1.3 are regarded as normal, <0.75 as loss, and >1.3 as gain. 14, 21 
Data Collection and Statistical Analysis
To obtain saliva MLPA norms, we estimated 99.99% confidence intervals (CIs) on normal controls. Given the result, we decided to use the numerical copy numbers for analysis to obtain more information from the data collected.
To discriminate HNSCC patients from normal controls, genetic alterations identified in saliva DNA were analyzed using the Classification and Regression Tree (CART) statistical tool to generate gene-based algorithms. CART methodology, known as binary recursive partitioning, uses nonparametric approaches. 16, 23, 24 Given the large number of genes (82 variables) and a small data set with 37 subjects to avoid the overfitting, we first performed CART on all genes and ranked them on the basis of their individual importance from high (eg, 100%) to low (0%), which is similar to conducting univariate analyses before multivariable modeling using logistic regression. Variables with a ranking of 20% or higher were included in the CART model for discrimination analysis.
In the multivariable modeling process, CART identifies the first gene probe variable with the greatest predictive power and divides the subjects into 2 groups of HNSCC and normal (Fig. 2 ). It will then identify a second gene probe with the next highest predictive power to further partition subjects. The process continues until further partitioning is exhausted.
After CART created a discrimination model based on all subjects, referred to as ''learning data,'' this model was validated using the leave-one-out validation approach, called the ''testing'' data. Leave-one-out crossvalidation is the statistical practice of partitioning a sample of data into subsets such that the analysis is initially performed on a single subset, whereas the other subsets are retained for subsequent use in confirming and validating the initial analysis. A single observation from the original sample is used as the validation data and the remaining observations as the training data. This is repeated such that each observation in the sample is used once as the validation data.
Sensitivity and specificity measures and their 95% CIs were calculated on the basis of the testing data set using the Exact analytical approach.
RESULTS
Of the 37 subjects analyzed, 27 were HNSCC patients, 85% males, age 22 to 81 years (mean 57; median 56 y), 11 (41%) early stage (I/II) tumors. Ten were healthy normal controls, 20% males, age 20 to 50 years (mean 37.2; median 35 y). The 99.99% CIs of the saliva gene copy numbers are presented in Table 1 on the basis of 10 normal controls. The 99.9% CI for normality of each gene probe in the normal control group remained within the expected range for normal copy number, 21 but the norms were much tighter for supporting the use of the numerical raw data rather than the categorical data [on the basis of arbitrary cutoffs of 1.33 (gain) and 0.75 (loss)]. 21 Eleven genes (ERBB2, ABCC4, UTY, DNMT1, PMAIP1, CDKN2B, CDKN2D, NFKB1, TP53, PTPN1, and DCC), with the highest ranking (20% or higher, Table 2 ), were included in the multivariable classification modeling.
CART identified 2 gene probes (PMAIP1 and PTPN1) that classified the study subjects into either the HNSCC group or the normal control group with 0 error rate on the learning samples (Table 3 ). Assuming a value of 2 as the cutoff point for gain, on the basis of ''learning'' samples, subjects with gain of PMAIP1 solely, or with concomitant gain of PTPNI, were 100% correctly classified into the HNSCC group (Fig. 2) . Subjects, on the other hand, who had loss or normal copy of PTPNI and PMAIP1 were 100% correctly classified into the normal control group (Fig. 3) . The sensitivity and specificity were 100% for both with 95% lower bound interval as 87.2% and 69.2%, respectively.
The leave-one-out validation misclassified 3 subjects; 2 normal controls were misclassified as HNSCC and 1 HNSCC was misclassified as a normal control. On the basis of these results, the sensitivity and specificity were 
DISCUSSION
HNSCC continues to pose a clinical challenge despite rapid advances in therapeutic options. Late detection is the single most important factor in the poor prognosis of HNSCC. Early diagnosis will significantly help in reducing the mortality and morbidity associated with HNSCC.
Several consistent genetic alterations have been described in HNSCC at 3p, 4q, 5q, 6p, 9p, 11q, 13q, 17p, 18q, and 20q. [11] [12] [13] [14] However, no single gene alteration is exclusive for HNSCC. There is a need to identify HNSCC-specific genetic alterations that can potentially be used as biomarkers for early diagnosis, screening, prognosis, and treatment of HNSCC. They can also assess risk for HNSCC, assist in tumor surveillance, and monitor disease progression.
Saliva, a noninvasive patient sample, promises to revolutionize diagnostic medicine as it can reflect the entire spectrum of health and disease states. 25 Its advantages over serum samples include ease of collection, storing, shipping, and handling, as it does not clot, thereby lessening the manipulations required. It dramatically reduces patient anxiety and discomfort allowing repeated samples for monitoring over time. The initial notion that informative analytes are generally present in lower amounts in the saliva than in serum 26 have now been allayed with new and highly sensitive analytical techniques. 25 Newly developed high-throughput analytical methods in the fields of molecular biology and genetic medicine have enabled detailed molecular characterization of cancer. The present study demonstrates the efficacy of MLPA for simultaneous interrogation of several genes in scant amounts of saliva DNA. In our study, the 99.9% CI for normality of each probe in the normal control group remained, in large part, within the expected range for normal copy number and is consistent with published results. 21 Our confidence limits were narrower with less variation in the CIs when compared with other studies, 21 stressing reliability of the data.
CART analysis is a statistical tool used to extract pertinent information from extremely complex data sets. In the current analysis, its ability to separate data sets on the basis of numeric or categorical variables and delineating useful genes from insignificant ones was emphasized, as its utility has been demonstrated in previous studies. 16 It produces decision trees, on the basis of simple yes/no questions, revealing relationships that are sometimes hidden. CART is more likely to be practical in a clinical setting as it is much simpler to interpret than multivariate logistic regression models. The advantages of CART, compared with the usual logistic regression are (i) there is no assumption requirement for the covariate (eg, the linear of log odd required for a logistic model), (ii) there is no prespecified cutoff point for each covariate (CART will explore all the possible cutoffs for each gene and generate the best cutoff point on the basis of predictive ability), (iii) it allows the assessment of gene by gene variable interaction if any, and (iv) it generates discriminatory models, preferable to association studies. In the leave-one-out validation, one of CART's validation methods, all of the data are used for fitting (but not at the same time) providing prediction capabilities usually requiring larger data sets, leading to smaller prediction errors, and a superior outcome for small data sets, compared with split-sample validation. 27 The present study demonstrates proof of concept that saliva gene-based algorithms can differentiate HNSCC patients from normal controls using highthroughput MLPA assays. In our ongoing study, we are currently analyzing genetic alterations in HNSCC patients and comparing them with high-risk patient controls who are smokers and alcohol consumers.
In the present analysis, CART discriminated HNSCC from normal controls on the basis of 2 gene variables (Fig. 2 importance in CART was an arbitrary cutoff point, and it can be varied on the basis of sample size. Cutoffs of 40% or more yield only 6 gene variables for inclusion in the multivariable model with a resulting sensitivity and specificity of 100% (87.2% to 100%) and 80% (44%, 97.5) on the basis of the testing data set. When all 82 gene variables, as an extreme scenario, are included, the same 2-gene classification model is identified with 100% accuracy on the basis of the learning data set, but sensitivity and specificity are reduced to 77.8% (57.7% to 91.4%) and 80% (44.4%, 97.5). In the present study, the sample size, especially the sample size for controls is small and the analysis results should be regarded as exploratory. The present study included 41% early stage lesions, indicating the ability of this noninvasive approach to identify both early and late-stage HNSCC. Although not as yet tested, there is great potential that these methods may provide the ability to identify early cancers before their gross clinical manifestations. This may be particularly important in high-risk patients. The study cases included 74% nonoral cavity HNSCC, providing proofof-concept that saliva-based genetic test has the potential to detect nonoral cavity cancers.
In summary, the combination of 2 genes, gain of PMAIP1 (18q21.31) solely or in conjunction with gain of PTPN1 (20q13.13), in saliva DNA can differentiate HNSCC cases from normal controls with high sensitivity and specificity. Our study demonstrates that saliva genomics may have clinical utility for noninvasive HNSCC detection and screening. Molecular targets contained within CART gene algorithms would emphasize these genes as relevant biomarkers for screening, early detection, prognosis, and treatment in HNSCC. Additionally, these findings would enhance our understanding of the pathogenesis of HNSCC.
